Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT01140373
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
- NCT01140373 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused
We haven't built an HCP commentary report on NCT01140373 (cyclophosphamide in castrate metastatic prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT01140373 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- engineered autologous T cells; cyclophosphamide
- Arms
- autologous T cells & cyclophosphamide. · Experimental
- Enrollment
- 13
- Primary outcomes
- The safety and tolerability of immunotherapy
- Sponsor
- Memorial Sloan Kettering Cancer Center with United States Department of Defense
- Start
- Jun 2010
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT01140373 · updated Jul 7, 2026